Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prevest DenproBOM:543363 +0.78%84 EBITDA Margin % is 43.91% as of Mar. 2026, which is 7% above its 10-year median of 40.94. GuruFocus rates BOM:543363 with a GF Score™ of 84/100 and a GF Value™ of ₹622.13 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Prevest Denpro ranks better than 96.81% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Prevest Denpro's EBITDA for the
three
months ended in Mar. 2026 was ₹83.2 Mil. Prevest Denpro's Revenue for the
three
months ended in Mar. 2026 was ₹189.4 Mil. Therefore, Prevest Denpro's EBITDA margin for the quarter that ended in Mar. 2026 was 43.91%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Prevest Denpro EBITDA Margin % Related Terms
Prevest Denpro EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Prevest Denpro's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543363 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Prevest Denpro's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prevest Denpro EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Prevest Denpro's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Prevest Denpro's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prevest Denpro (BOM:543363) has a EBITDA Margin % of 43.91% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Prevest Denpro and its competitors. This is near median its historical median of 40.94. Over the past decade, Prevest Denpro's EBITDA Margin % has ranged from 22.35 to 43.77. According to the industry distribution chart, Prevest Denpro ranks #26 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 3.2%.
Is Prevest Denpro's EBITDA Margin % too high?
Prevest Denpro's current EBITDA Margin % of 43.91% is near median its 10-year median of 40.94. Over the past 10 years, this metric has ranged from a low of 22.35 to a high of 43.77. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Prevest Denpro's value of 43.91% is 487% above this industry median. Based on the distribution chart, Prevest Denpro ranks #26 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Prevest Denpro has a GF Score™ of 84/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Prevest Denpro's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Prevest Denpro ranks #26 out of 815 companies for EBITDA Margin %. This places Prevest Denpro in the top 3% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Prevest Denpro's value of 43.91% is 487% above this benchmark. Historically, Prevest Denpro's own EBITDA Margin % has ranged from 22.35 to 43.77 over the past decade. While the company's 10-year median is 40.94 vs. the industry median of 7.48, Prevest Denpro has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prevest Denpro's current EBITDA Margin % of 43.91% is 487% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Prevest Denpro and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prevest Denpro's current EBITDA Margin % is 43.91%, which is near median its own 10-year median of 40.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prevest Denpro stock overvalued right now?
Based on GuruFocus' analysis, Prevest Denpro (BOM:543363) is currently considered Possible Value Trap. The stock's GF Value™ is ₹622.13, compared to a current price of ₹390.00 — trading 37.3% below its estimated fair value. The current EBITDA Margin % is 43.91%, which is near median its 10-year median of 40.94 and 487% above the Medical Devices & Instruments industry median of 7.48. Prevest Denpro's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Prevest Denpro (BOM:543363), the current EBITDA Margin % is 43.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prevest Denpro (BOM:543363) Overvalued in 2026?
Based on GuruFocus' analysis, Prevest Denpro stock appears to be undervalued.
The current stock price of ₹390.00 is trading 37.3% below its estimated GF Value™ of ₹622.13.
GuruFocus considers Prevest Denpro to be Possible Value Trap.
Key valuation signals for BOM:543363:
EBITDA Margin %: 43.91% (near median its 10-year median of 40.94)
GF Value™: ₹622.13 vs. price of ₹390.00 (37.3% below fair value)
Industry Position: 487% above the Medical Devices & Instruments median (#26 of 815)
No single metric tells the full story. See the BOM:543363 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prevest Denpro Ltd develops, manufactures and markets a comprehensive portfolio of dental materials for diagnosing, treating and preventing dental conditions as well as improving the aesthetics of the human smile. The company's product portfolio covers wide spectrum of materials for endodontics, prosthodontics, orthodontics, periodontics, restorative dentistry, aesthetic dentistry and laboratory consumables.
84GF Score
Get the complete analysis for BOM:543363
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543363 has been successfully added to your 
